Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Slow-Release caffeine may boost morning mood without the jitters

NCT ID NCT06441695

Symptom relief Sponsor: Applied Science & Performance Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a slow-release caffeine pill (zümXR) could improve mood, alertness, and reduce side effects like jitters compared to regular caffeine after a night of poor sleep. Thirty-six healthy adults who usually drink moderate amounts of caffeine took part. They slept less than 5 hours, then took either the slow-release or regular caffeine and reported how they felt over several hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extended-release caffeine
What this could lead to
If it works, this could offer a way to stay alert after a bad night's sleep with less jitteriness or anxiety than regular caffeine.
What could go wrong
This is a small, early study with only 36 people, so results may not apply to everyone. The effects are short-term and not a substitute for proper sleep.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Jun 2024

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female aged 35-50 years (both limits inclusive); * Body mass index (BMI) of 18.50-29.99 kg/m2 -Habitual moderate caffeine consumers (200-400 mg/day) assessed through caffeine assessment tool (Caffeine - * Consumption Questionnaire, CCQ); * Intermediate chronotype (\>31 or \<69 on Morningness-Eveningness Questionnaire). Exclusion Criteria: * Subjects presenting any of the following will not be included in the study: * No history of anxiety disorders or sleep disorders; * Non-smokers; * Alcohol consumption 72 hours prior to the start of study/consumption of study product; * No use of sleep medicines, melatonin, marijuana within two weeks of start of study; * No travel involving time zone change, shift work, or other life events that alter sleep schedule \>3 hours from the norm one week before the start of study (assessed using sleep-wake schedule diary for week prior to study); * Caffeine restricted past 12 PM from the day prior to the start of study (verify through caffeine diet history).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caffeine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cognitive disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Caffeine Cognitive change MOOD Mood change

Contacts and locations

Locations

  • Applied Science & Performance Institute

    Tampa, Florida, 33634, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.